Cargando…
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
BACKGROUND: Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment. Adalimumab, a tumour necrosis factor (TNF)-alpha inhibitor, effectively controls joint and eye inflammation; however, its long-term use may i...
Autores principales: | Acharya, Nisha R., Ebert, Caleb D., Kelly, Nicole K., Porco, Travis C., Ramanan, Athimalaipet V., Arnold, Benjamin F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590716/ https://www.ncbi.nlm.nih.gov/pubmed/33109240 http://dx.doi.org/10.1186/s13063-020-04796-z |
Ejemplares similares
-
Juvenile idiopathic arthritis-associated uveitis
por: Clarke, Sarah L. N., et al.
Publicado: (2016) -
Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
por: Zholobova, Elena, et al.
Publicado: (2014) -
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
por: Lanz, Sofia, et al.
Publicado: (2021) -
Juvenile Idiopathic Arthritis Associated Uveitis
por: Carlsson, Emil, et al.
Publicado: (2021) -
Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)